"Everything comes from somewhere, and we believe we found the origin of immunoglobin Joining chain (J chain), an important immune molecule ... of antibodies, called immunoglobin M (IgM) and ...

MGD010 exhibited pharmacokinetic properties of an antibody-based molecule, with dose-dependent B-cell occupancy ... and CD40 expression as well as a moderate decrease in total serum IgM levels.

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

“I want to thank our colleagues who will be departing from IGM as part of the restructuring and acknowledge their many contributions to our programs,” added Dr. Harler. “We are grateful for ...

both IgM-based bispecific antibody T cell engagers, for autoimmune diseases. Imvotamab or CD20 x CD3 is a bispecific IgM antibody that targets CD20 and CD3 proteins. It has 10 binding units for ...

IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The ...

Bank of America Securities analyst Charlie CY Yang maintained a Hold rating on IGM Biosciences (IGMS – Research Report) today. The company’s ...

IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%. The biotechnology ...

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...